Future areas for consideration of measure development include chronic liver disease, colorectal cancer screening, adverse events related to colonoscopy, assessing the quality of colonoscopy, gastroesophageal reflux disease and cirrhosis measures, and Barrett’s esophagus.
“I think it is an appropriate set of metrics for gastroenterology and hepatology,” said Dr. Gellad. “It was a collaborative approach. We had influence over the measures that were chosen for our specialty, but not the final say.”
